Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)

NCT05101122 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Obstructive Sleep Apnea

Interventions

DRUG: Dosing 1: Atomoxetine
DRUG: AD313

Sponsor

Apnimed